- Home
- ACIU vs SLND Comparison
ACIU vs SLND Comparison
Compare ACIU & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- SLND
- Stock Information
- Founded
- ACIU 2003
- SLND 1900
- Country
- ACIU Switzerland
- SLND United States
- Employees
- ACIU N/A
- SLND N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- SLND Military/Government/Technical
- Sector
- ACIU Health Care
- SLND Industrials
- Exchange
- ACIU Nasdaq
- SLND Nasdaq
- Market Cap
- ACIU 213.3M
- SLND 210.6M
- IPO Year
- ACIU 2016
- SLND N/A
- Fundamental
- Price
- ACIU $2.97
- SLND $3.19
- Analyst Decision
- ACIU Strong Buy
- SLND Hold
- Analyst Count
- ACIU 2
- SLND 1
- Target Price
- ACIU $10.00
- SLND $4.00
- AVG Volume (30 Days)
- ACIU 266.4K
- SLND 71.3K
- Earning Date
- ACIU 11-04-2025
- SLND 11-12-2025
- Dividend Yield
- ACIU N/A
- SLND N/A
- EPS Growth
- ACIU N/A
- SLND N/A
- EPS
- ACIU N/A
- SLND N/A
- Revenue
- ACIU $5,482,957.00
- SLND $935,461,000.00
- Revenue This Year
- ACIU N/A
- SLND N/A
- Revenue Next Year
- ACIU $1,022.98
- SLND $3.50
- P/E Ratio
- ACIU N/A
- SLND N/A
- Revenue Growth
- ACIU N/A
- SLND N/A
- 52 Week Low
- ACIU $1.43
- SLND $2.68
- 52 Week High
- ACIU $4.00
- SLND $5.34
- Technical
- Relative Strength Index (RSI)
- ACIU 44.78
- SLND 34.47
- Support Level
- ACIU $2.70
- SLND $2.85
- Resistance Level
- ACIU $3.13
- SLND $3.42
- Average True Range (ATR)
- ACIU 0.21
- SLND 0.34
- MACD
- ACIU -0.05
- SLND -0.06
- Stochastic Oscillator
- ACIU 32.50
- SLND 12.05
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.